Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review
| Autor: | C. Belén Congregado-Ruíz, Guillermo Lendínez-Cano, Cristina Baena-Villamarin, Ignacio Osmán-García, Jose Manuel Conde-Sanchez, Rafael Antonio Medina-López |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Male medicine.medical_specialty Urology medicine.medical_treatment Metastatic renal cell carcinoma Peritoneal dialysis 030232 urology & nephrology Renal function urologic and male genital diseases Drug Administration Schedule End stage renal disease 03 medical and health sciences End-stage renal disease 0302 clinical medicine Antineoplastic Agents Immunological Renal cell carcinoma Renal Dialysis Internal medicine medicine Humans Carcinoma Renal Cell Dialysis Aged business.industry Middle Aged medicine.disease Kidney Neoplasms Clinical trial Haemodialysis Nivolumab Treatment Outcome 030220 oncology & carcinogenesis Kidney Failure Chronic business Progressive disease |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname |
| ISSN: | 1423-0399 |
| Popis: | Nivolumab is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody that selectively blocks the interaction between PD-1, which is expressed on activated T cells, and its ligands PD-L1 and PD-L2, which are expressed on immune cells and tumour cells. Patients with severe renal dysfunction and haemodialysis are not enrolled in clinical trials. However, in daily clinical practice, we have patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD). The scientific evidence about the efficacy and safety of nivolumab in these patients is scarce. We report three cases of mRCC patients with ESRD treated with second-line nivolumab therapy. They received both biweekly and monthly schemes. None of our patients showed grade 2–4 toxicities. Two patients achieved partial response and one progressive disease as best response. Our patients did not show increased toxicity by ESRD; also, two of the three patients had objectifiable clinical benefit. Nivolumab seems to be similarly safe for ESRD or dialysis patients as for patients without impaired kidney function (IKF). Dose adjustments might not be necessary. We suggest that patients on dialysis could be treated with nivolumab in the same way as populations without IKF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|